Cargando…

rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461

Hyperactivation of RNA polymerase I (Pol I) transcription of ribosomal RNA (rRNA) genes (rDNA) is a key determinant of growth and proliferation and a consistent feature of cancer cells. We have demonstrated that inhibition of rDNA transcription by the Pol I transcription inhibitor CX-5461 selectivel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Son, Jinbae, Hannan, Katherine M., Poortinga, Gretchen, Hein, Nadine, Cameron, Donald P., Ganley, Austen R. D., Sheppard, Karen E., Pearson, Richard B., Hannan, Ross D., Sanij, Elaine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349920/ https://www.ncbi.nlm.nih.gov/pubmed/32719798 http://dx.doi.org/10.3389/fcell.2020.00568

Ejemplares similares

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling
por: Quin, Jaclyn, et al.
Publicado: (2016)

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation
por: Diesch, Jeannine, et al.
Publicado: (2019)

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer
por: Sanij, Elaine, et al.
Publicado: (2020)

The therapeutic potential of RNA Polymerase I transcription inhibitor, CX-5461, in uterine leiomyosarcoma
por: Kang, Chang-Won, et al.
Publicado: (2022)

CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer
por: Xuan, Jiachen, et al.
Publicado: (2020)

The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer
por: Yan, Shunfei, et al.
Publicado: (2020)

The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer
por: Yan, Shunfei, et al.
Publicado: (2017)

c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation
por: Poortinga, Gretchen, et al.
Publicado: (2011)

CX-5461 induces radiosensitization through modification of the DNA damage response and not inhibition of RNA polymerase I
por: Lehman, Stacey L., et al.
Publicado: (2022)

Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis
por: Kerry, Louise E., et al.
Publicado: (2017)

Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription
por: Kang, Jian, et al.
Publicado: (2016)

CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response
por: Snyers, Luc, et al.
Publicado: (2022)

Therapeutic efficacy of the novel selective RNA polymerase I inhibitor CX‐5461 on pulmonary arterial hypertension and associated vascular remodelling
por: Xu, Xia, et al.
Publicado: (2021)

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer
por: Cornelison, Robert, et al.
Publicado: (2021)

The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers
por: Ismael, Mohammed, et al.
Publicado: (2019)

Alternative splicing of human telomerase reverse transcriptase in gliomas and its modulation mediated by CX-5461
por: Li, Guihong, et al.
Publicado: (2018)

CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage
por: El Hassouni, Btissame, et al.
Publicado: (2019)

Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461
por: Masud, Tehmina, et al.
Publicado: (2021)

The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability
por: Mars, Jean-Clément, et al.
Publicado: (2020)

A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes
por: Sanij, Elaine, et al.
Publicado: (2015)

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours
por: Xu, Hong, et al.
Publicado: (2017)

A positive role for yeast extrachromosomal rDNA circles?
por: Poole, Anthony M, et al.
Publicado: (2012)

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma
por: Pan, Min, et al.
Publicado: (2021)

A transcriptional program associated with cell cycle regulation predominates in the anti-inflammatory effects of CX-5461 in macrophage
por: Wang, Jie, et al.
Publicado: (2022)

Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease
por: Diesch, Jeannine, et al.
Publicado: (2014)

Genome wide mapping of UBF binding-sites in mouse and human cell lines
por: Diesch, Jeannine, et al.
Publicado: (2015)

CX-5461 induces autophagy and inhibits tumor growth via mammalian target of rapamycin-related signaling pathways in osteosarcoma
por: Li, Leiming, et al.
Publicado: (2016)

UBF levels determine the number of active ribosomal RNA genes in mammals
por: Sanij, Elaine, et al.
Publicado: (2008)

CX-5461 Enhances the Efficacy of APR-246 via Induction of DNA Damage and Replication Stress in Triple-Negative Breast Cancer
por: Makhale, Ashwini, et al.
Publicado: (2021)

Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells
por: Negi, Sandeep S., et al.
Publicado: (2015)

Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies
por: Hilton, John, et al.
Publicado: (2022)

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis
por: Kusnadi, Eric P, et al.
Publicado: (2020)

Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers
por: Udugama, Maheshi, et al.
Publicado: (2018)

rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis
por: Negi, Sandeep S., et al.
Publicado: (2015)

Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer
por: Hein, Nadine, et al.
Publicado: (2017)

The Ribosomal Gene Loci—The Power behind the Throne
por: Panov, Konstantin I., et al.
Publicado: (2021)

A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer
por: Chung, Shin-Yi, et al.
Publicado: (2022)

Targeting RNA Polymerase I Transcription Activity in Osteosarcoma: Pre-Clinical Molecular and Animal Treatment Studies
por: Kang, Chang-Won, et al.
Publicado: (2023)

Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age
por: Ferreira, Rita, et al.
Publicado: (2020)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer
por: Inderjeeth, Andrisha-Jade, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_41l2mc62pmnovlnj0pjorimu4a